Discussion
Clene Nanomedicine has submitted an application to the U.S. Food and Drug Administration (FDA) seeking accelerated approval of its experimental oral therapy CNM-Au8 for people with amyotrophic lateral sclerosis (ALS). The new drug application (NDA), submitted earlier this month, is supported mainly by clinical data suggesting that CNM-Au8…